Tech Company Financing Transactions

Scholar Rock Funding Round

Scholar Rock closed a $47 million Series C investment round on 1/4/2018. Investors included Invus, Arch Venture Partners and Cormorant Asset Management.

Transaction Overview

Company Name
Scholar Rock
Announced On
1/4/2018
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series C
Investors

Invus (Lead Investor)

Arch Venture Partners (Kristina Burow)

Cormorant Asset Management

EcoR1 Capital Management

Fidelity Management & Research Company

private investors (Timothy Springer)

Polaris Partners (Amir Nashat)

Redmile Group

The Kraft Group

Proceeds Purpose
Proceeds from the financing will be used to advance SRK-015, the company's lead clinical candidate for Spinal Muscular Atrophy (SMA) and other neuromuscular disorders, into clinical development in the first half of 2018.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 2nd Floor
Cambridge, MA 02139
USA
Phone
(857) 259-3860
Website
www.scholarrock.com
Email Address
[email protected]
Overview
Scholar Rock is discovering and developing a new class of biologic therapies to selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation, resulting in therapeutic effects specifically at the source of disease.
Profile
Scholar Rock LinkedIn Company Profile
Social Media
Scholar Rock Company Twitter Account
Company News
Scholar Rock News
Facebook
Scholar Rock on Facebook
YouTube
Scholar Rock on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nagesh Mahanthappa
  Nagesh Mahanthappa LinkedIn Profile  Nagesh Mahanthappa Twitter Account  Nagesh Mahanthappa News  Nagesh Mahanthappa on Facebook
Chief Financial Officer
Rhonda Chicko
  Rhonda Chicko LinkedIn Profile  Rhonda Chicko Twitter Account  Rhonda Chicko News  Rhonda Chicko on Facebook
Chief Medical Officer
Yung Chyung
  Yung Chyung LinkedIn Profile  Yung Chyung Twitter Account  Yung Chyung News  Yung Chyung on Facebook
Chief Operating Officer
Elan Ezickson
  Elan Ezickson LinkedIn Profile  Elan Ezickson Twitter Account  Elan Ezickson News  Elan Ezickson on Facebook
Chief Scientific Officer
Alan Buckler
  Alan Buckler LinkedIn Profile  Alan Buckler Twitter Account  Alan Buckler News  Alan Buckler on Facebook
Vice President
Gregory Carven
  Gregory Carven LinkedIn Profile  Gregory Carven Twitter Account  Gregory Carven News  Gregory Carven on Facebook
VP - Bus. Development
Dodzie Sogah
  Dodzie Sogah LinkedIn Profile  Dodzie Sogah Twitter Account  Dodzie Sogah News  Dodzie Sogah on Facebook
VP - General Counsel
Junlin Ho
  Junlin Ho LinkedIn Profile  Junlin Ho Twitter Account  Junlin Ho News  Junlin Ho on Facebook
VP - Human Resources
Stephen Burke
  Stephen Burke LinkedIn Profile  Stephen Burke Twitter Account  Stephen Burke News  Stephen Burke on Facebook
VP - Operations
Ryan Iarrobino
  Ryan Iarrobino LinkedIn Profile  Ryan Iarrobino Twitter Account  Ryan Iarrobino News  Ryan Iarrobino on Facebook
VP - Regulatory Affairs
Heather Faulds
  Heather Faulds LinkedIn Profile  Heather Faulds Twitter Account  Heather Faulds News  Heather Faulds on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/4/2018: Recros Medica venture capital transaction
Next: 1/4/2018: Ecochlor venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.